Summit Therapeutics Inc.

Good morning and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call. All participants will be able to listen only until the question and answer portion of this call. We do not expect any technical difficulties today. However, in the event that we lose the webcast connection and we are unable to provide any updates, please wait up to 10 minutes for resolution. Please refer to the company's website for updates. Please note that today's call is being recorded. To ask a question, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again press star one. At this time, I would like to introduce the call to Dave Gancars, Chief Business and Strategy Officer. You may proceed.

Thank you for joining us. Our press release was issued earlier this morning and is available on the home page of our website. Our Form 10Q was also filed earlier this morning and is available on our website. Today's call is being simultaneously webcast and an archived replay will be available later today on our website .smmttx.com. Joining me on the call today is Bob Duggan, our Chairman of the Board and Chief Executive Officer. Dr. Mekki Zangade, our Chief Executive Officer and President. Ankur Dhingra, our Chief Financial Officer. Dr. Alan Yang, our Chief Medical Officer. And in addition, we are joined by our new Chief Operating Officer, Manmeet Soni. Manmeet joins us from Raiatta Pharmaceuticals where he was the President, Chief Operating Officer and Chief Financial Officer. Raiatta was recently purchased by Biogen for approximately $7.5 billion. Manmeet was previously the CFO at Allen Island Pharmaceuticals and Aria Pharmaceuticals. Before that, he was the CFO of Pharmacyclics. Manmeet will continue to serve on our board and he also serves on the Board of Pulse Biosciences. Manmeet will be responsible for all commercial activities, finance, clinical operations, manufacturing, legal, information technology and human resources. In conjunction with Manmeet joining us, he invested $5 million in the company and a private placement at MarketRace. We are excited to have Manmeet join Team Summit and welcome Manmeet to the team.

Thanks Dave. I'm very excited to be here and be part of Team Summit. I've worked with the team here at Summit for the last four years as a board member and I'm very thrilled to join the team. I strongly believe that our pipeline candidate, Yvonne Smab, with two phase three clinical trials currently enrolling in the United States, Canada, Europe and China has the potential to bring a paradigm shift in the standard of care for patients with solid tumors starting with non-small cell lung cancer. I'm fully committed to our mission of developing new innovative and friendly medicines for on-met medical needs and I'm excited to contribute to making this positive meaningful difference.

Thanks Manmeet. Before we get started with the rest of the call, I would like to note that some statements made by our management team and some responses to questions that we make today may be considered forward-looking statements based on our current expectations. Summit cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Please refer to our SEC filings for information about these risks and uncertainties. Summit undertakes no obligation to update these forward-looking statements except as required by law. Following comments from Bob, Maki and Ankur, we will take questions. With that, I will turn the call over to

Bob. Thank you Dave. Good morning everyone and thank you for joining us today. I'd like to say a few words about what Team Summit has accomplished. Then I will hand it over to Maki to add more color and then Ankur will provide some updates regarding our financial position and current outlook. I'm very proud of the efforts and accomplishments of Team Summit since we have entered into our very fruitful partnership with the KESOL. As we announced this morning, we have begun enrolling in our second phase three clinical trial, Armini 3, in frontline population of patients suffering from squamous cell carcinoma of the lung. This is our second phase three non-small cell lung cancer trial that is designed with registrational intent. We have accomplished this based on and driven by conviction in our belief in Ibanezumab. In just nine months since we have closed our deal to in-license Ibanezumab, we have achieved these milestones with the intent of helping patients who need continuous innovation to improve quality of life and potential duration of life consistent with our mission at Summit. Dedication to our mission and collapsing time when and where possible has provided Maki and me, along with our team, with success in the past. Whether in networking technology, robotic surgery, or with that brood can be the case of pharmacics, once again, we are committed to making a positive difference for patient betterment in the area of solid tumors. I'm also very proud of the organization that we have that we continue to strengthen at Team Summit. Highlighting this is the decision of Manmeet Soni to join us full-time as our chief operating officer. Manmeet is a seasoned executive with an excellent track record of success, as Dave highlighted earlier. He has also been a board member and trusted advisor of the company since 2019. As executive of the caliber of Manmeet, joining our company and believing in our mission and pipeline in addition to his personal investment validates the confidence we have in our intention to make a significant positive difference to those patients who could benefit most from the work we are doing. Also, in consideration of the accomplishments we have had as an organization, we've also elevated a number of specific members of our management team. Fong Clow is our new chief biometrics officer. Dave Gansgard is now our chief business and strategy officer. Ulta Geico is our chief regulatory, quality, and safety officer. And Allen Yang is now our chief medical officer. This team works tirelessly to advance Summit along with each of the leaders and team members that comprise our team. With that, I would like to hand it over to Maki to provide additional context as to our accomplishments and next steps. Maki?

Thank you, Bob, and good morning, everyone. I'm incredibly enthusiastic about Ibanezimab with potential and what Team Summit has already accomplished. As Bob said, we threw conviction and purpose along with our belief in Ibanezimab to help accomplish our mission to benefit patients facing difficult odds with unmet medical needs comes the incredible power of execution of Team Summit at speed accomplished by few, if any, in the biotech space. We now have two actively enrolling phase three clinical trials for Ibanezimab. Our first trial is for those patients with non-small cell lung cancer harboring EGFR mutations who have progressed following a third generation TKI such as Tachyrosa. We began enrolling patients in the second quarter of this year, and we can now state that we intend to complete enrollment in the second half of 2024. As we have committed to along our tenure here at Summit, we work tirelessly to collapse time in order to achieve our aggressive but realistic goals. Our second phase three clinical trial for Ibanezimab is in front-line therapy. Those who have not yet received treatment for patients with squamous cell carcinoma of the lung. We will enroll patients in this trial across North America, Europe, and China. The trial is designed to compare Ibanezimab and chemotherapy against K-Truda and chemotherapy in order to determine the efficacy and safety of our innovative by specific antibody in this setting. Our convention to move forward with all appropriate speed has been in place since we worked through our due diligence Ibanezimab with ECHESO. Obviously, our upfront payment of 500 million to ECHESO spoke volumes about our conviction and belief in Ibanezimab. Disclosed in part at ASCO 2023, the large data set that ECHESO has generated backs up our conviction, how Ibanezimab plus chemotherapy performed in phase two clinical trials supports our decision to quickly pursue a registration of phase three study. We believe that the study data is very promising when compared with the current standard of care, K-Truda plus chemotherapy, and supports our decision to directly move forward into first line therapy with our second phase three clinical trial. In collaboration with our partners at ECHESO, we published a poster further describing a mechanism of action of Ibanezimab at the 38th annual meeting of the Society of Immunotherapy of Cancer, CITC 2023, one of the premium conferences of the year. Ibanezimab is not designed to be the same as the sequential administration of an -PD-1 and then an anti-VGF. Ibanezimab is an innovative, potentially first in class by specific antibody that builds on these two established cancer targets. Ibanezimab tetravalent structure enables cooperative binding between PD-1 and VGF. Our poster at CITC 2023 described that the binding of Ibanezimab to PD-1 is actually over 18 times stronger in the presence of VGF in vitro. In addition, its binding affinity to VGF is over fourfold stronger in the presence of PD-1 in vitro. Importantly, there is potentially higher expression or presence

of VGF. Okay. Okay. Ladies and gentlemen, this is the operator. We've had some technical difficulties. Please remain on line.

Thank you. Thank you. Thank you, ladies and gentlemen. We apologize

for the technical issues. I'll hand it back over to Maki to continue with her comments. Maki?

Thank you, Dave. Continue. Ibanezimab is not designed to be the same as the sequential administration of an -PD-1 and then an anti-VGF. Ibanezimab is an innovative, potentially first in class by specific antibody that builds on these two established cancer targets. Ibanezimab tetravalent structure enables cooperative binding between PD-1 and VGF. Our poster at CIDC 2023 described that the binding of Ibanezimab to the PD-1 is actually over 18 times stronger in the presence of VGF in vitro. In addition, its binding affinity to VGF is over fourfold stronger in the presence of PD-1 in vitro. Importantly, there is potentially higher expression or presence of both PD-1 and VGF in tumor tissue and the tumor microenvironment. The area around the tumor as compared to normal tissue in the body. The tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single by specific antibody with cooperative binding qualities have the potential to direct Ibanezimab to the tumor tissue versus healthy tissue. -PD-1 therapy assists the immune system in killing tumor cells by attaching to the part of a T cell that actually prevents the T cell from doing its job in the first place. Some cancer tumor cells take advantage of a built-in checkpoint on the T cell that is intended to prevent the immune system from overreacting. -PD-1 therapy seeks to bind to PD-1 on the T cell, allowing the T cell to do its job without a checkpoint or break. Hence, it's referred to as a checkpoint inhibitor. Anti-VGF therapy helps deplete the tumor of nutrition and blood by binding to VGF. VGF helps build new blood cells to supply blood to the tumor. Anti-VGF therapy also allows the immune system to better fight the tumor. We believe Ibanezimab goes further that the sequential administration of an -PD-1 and anti-VGF through this cooperative binding mechanism we just described. The intent, the stronger ability in this design is to improve upon previously established efficacy standards in addition to the side effects and safety profiles associated with these two targets. Ibanezimab was designed such that the novel compound is greater than just the sum of its parts. Our plans to continue to expand our clinical development program remain in place. Non-small cell lung cancer is only the first step. We have confidence in Ibanezimab to continue to expand both in additional indications in non-small cell lung cancer and in other solid tumors during its development life cycle. Our agreement with ECHESO was drawn up with this mindset. We believe strongly in the potential of Ibanezimab. We have begun accepting requests for investigator-sponsored trials, ISD programs. As we continue to broaden our message related to Ibanezimab with the key opinion leaders as well as other physician leaders, we appreciate their high level of enthusiasm for what Ibanezimab can do in and outside of lung cancer. We have received multiple inquiries related to potential ISD programs that we are considering and we expect to share additional information in 2024. Finally, I would like to say a word about our team. Based on the accomplishments of team summits over the last couple of years, we have elevated certain members of our management team. I congratulate Dave, Otto, Fong, and Alan in their well-deserved new roles. I'm also very excited we have been able to attract outstanding physicians to complete our clinical development leadership team. Dr. Jack West and Dr. Laura Chao have each joined us over the past months. They have over 45 years of combined experience as practicing medical oncologists as well as substantial experience in the development of cancer treatments that now represent some of the most significant cancer therapies in present time. Dr. Jack West is a renowned lung cancer expert and Dr. Laura Chao is a trailblazer in the novel immunotherapies and anti-angiogenic treatments primarily focused in lung cancer as well as head and neck cancer. Team Summit is a truly special place and I would like to thank each member of our amazing team for their dedication to our mission and roles. Now I will ask Unkar to provide additional details on our financial position and outlook. Unkar?

Thank you, Markey. Very pleased with the progress both in the development of Ibanez-Mab and continued build out of Team Summit. We believe Ibanez-Mab has excellent potential and continue to build our development plans towards realizing that. I will give you an update on the financial developments and position as well as financial outlook for the upcoming quarter. Regarding the P&L, majority of our spending is in research and development focused on development of Ibanez-Mab. We spent $15.2 million in R&D this quarter. As mentioned, we have engaged in two global phase three clinical trials for Ibanez-Mab both of which are enrolling and treating patients. We are also investing in technology transfer for manufacturing of Ibanez-Mab in our territory. We spent $5.4 million in general administration expenses during the quarter focused on providing infrastructure and leadership for our development efforts. We expect this quarterly run date of spending to continue to increase next quarter as well as in 2024 as we scale both pivotal studies, adding sites and treating patients as well as continue to build our team. Similarly, investment in manufacturing capabilities will continue to increase in next several quarters. At the same time, we continue to ensure that we remain disciplined in our approach of investment to extend our cash runway as long as possible. With respect to our cash position, we exited the quarter with $200.5 million in cash investments and receivables. We have a loan of $100 million that matures in September 2024. This loan has provided us significant non-diverted capital enabling a strong foundation for development of Ibanez-Mab via initiation of two pivotal clinical trials. Our cash position is sufficient to continue to make significant progress in the development of Ibanez-Mab by funding the operating costs and working capital needs for Harmony and Harmony B clinical profiles going into September 2024. As mentioned before, we continue to hold our cash equivalents in these investments in highly liquid and highly rated money market funds for the U.S. Treasuries and all the money is held in reputable U.S. and European banks. And with that, I'll hand it back over today.

Thank you, Bob, Mckee and Ankur. We can now transition to see if there are any questions from anyone on the line that we could answer. If you could please open the line for questions.

To ask a question, please press star 1. Please limit yourself to one question and one follow-up. We'll pause for just a moment to compile the Q&A roster. Again, to ask a question, please press star 1. Your first question is from Brad Cadino of Stifo. Please go ahead. Your line is open.

Good morning, team, and thank you for hosting the call and taking the question. This has been a really busy quarter of external phase 3 data disclosures in the tumor types for which you're developing Ibanez-Mab, things specifically of the data in EGFR mutant lung from amavantamab and then some of the Trope II ADCs broadly. In the later line setting, knowing that those will be investigated early on front line soon. It would be great to hear your view of this evolving competitive landscape and the opportunities that remain for Ibanez-Mab. Thank you.

Yeah, I don't think it really changes too much our landscape. You know, we're well underway in our phase 3 program for these EGFR refractory patients. You know, if you look at the Florida II data, it was really looking at the front line setting and I don't think that really changes our landscape, per se. And then I think you're talking about the Mariposa II data as well. You know, what we think about Osimertinib is that it is the standard of care for front line EGFR mutant lung cancer. But for those patients who relapse, we think that this is a great opportunity and we know that there's good data for Ibanez-Mab in this space. You know, if you look back, there is a failure of PD-1s in this space if you look at Pembroke and Evo. However, there is the Orient 31 study that looked at a PD-1 and Betasys and Meta-BioSimilar and that study was positive. Getting to LibraVance, you know, what we've heard from our sort of engagement with experts is that it is somewhat difficult to give and so we don't believe that will be significant competition. In addition, you know, the EGFR refractory spaces are fast to market strategy and then we're also simultaneously conducting a large front line study in swing on cell lung cancer.

Brad, do you have any follow up for that? That's it for me. Thank you so much. Thank you, Brad. Appreciate your question.

There are no further questions at this time. I will now turn the call over to Dave Gankars for closing remarks.

Thank you, Cheryl. And we have received a couple questions from our current shareholders that I'd like to address as well. And so, one of the questions relates to how clinical trials have progressed with respect to Aceso in China and Australia. And so, at this point in time, I'd like to address that piece and I'll hand it over to Alan for any additional points. But Aceso has 23 clinical trials at this point that have either been started or have completed at this point from phase one through phase three. So, they've treated over 950 patients with IVAN SMF and their clinical trials including the placebo arm or the active control arm have included, you know, well over a thousand patients. So, the significant experience building up with respect to IVAN SMF in particular in one of the settings, they will, Aceso will be looking to achieve approval in China in 2024 in the EGFR mutant setting in addition to continuing in multiple phase three settings in China and Australia. So, that data is continuing to grow and that growing data set continues to give us confidence in our progression within our clinical development plan as well.

Yeah, the only thing I would say is that, you know, this is a very unique molecule. So, maybe I can spend some time. This past weekend at CIDC there was a press release of McKee related earlier around the mechanism of action. So, we do target PD-1. So, PD-1, PD-L1 are well validated targets. PD-1, of course, seems to be more popular. IVAN SMF is a vice specific in the sense that it targets both PD-1 and VEGF. Now, there are other strategies targeting PD-L1 and VEGF, but I believe there is a difference and there was data released at this past ASCO for both IVAN SMF and a series of PD-L1 VEGFs. Now, IVAN SMF is also unique. Besides targeting two validated targets, PD-1 and VEGF, as McKee alluded to earlier, there's cooperative binding. The binding of PD-1 increases VEGF by fourfold and the binding of VEGF increases PD-1 binding by 18-fold. And so, theoretically, what you're going to have is the tightest binding at a location where both antigens exist, which is the tumor microenvironment. Now, the other thing to think about is that IVAN SMF is a tetravalent molecule. So, it has two binding sites for PD-1 and two binding sites for VEGF. VEGF is a secreted dimer by the tumors. And because of that, it can lead to potential cross-linking of two IVAN SMF molecules, and actually multiple IVAN SMF molecules. This is well described in the literature for Babicizumab, and we believe the same thing is happening for IVAN SMF. And that actually leads to a possibility of an increased avidity. So, there's affinity, the tighter binding between the cooperative binding, but then there's a possibility for avidity as well. So, the easiest way to think about this is if you think about one hand holding a handlebar with a tight grip, you know, using two hands to hold that sort of bar with both hands, that's the avidity phenomena. So, there's a tighter binding for affinity and a tighter binding for avidity as well. And so, we believe that this will have important differences in giving, as opposed to giving both of these agents separately. And the clinical data seems to support that, and we're moving very aggressively forward. Thank

you, Alan. And I think you've mainly addressed this. But then another question with respect to how does this differentiate from just a PD-1 agent on its own? So, a lot of approved PD-1 agents exist, Ambilizumab, Dibrallumab. If you can just kind of speak to a little bit of the difference there in terms of how it works.

Yeah. So, I thought I described that pretty well, if you want more detail. We could talk about the three-hour answers. I'll try to get the 30-second answer here. You know, maybe focusing on the MOA where we have both an affinity and avidity sort of phenomenon playing on the side of an estimate, we've been moving very aggressively based on the clinical trial data. If you look at all the PD-1s and less so the PD-L1s out there, they've pretty much done the same thing. They've gone into non-small cell lung cancer. They've compared themselves to chemotherapy. We believe that Ivanesumab is superior to PD-1 and PD-L1 therapy. To prove that, there are four phase 3s running, two global ones that are being conducted by Summit and then two Chinese specific studies that are being run by KESO. The partnerships, you've heard about the Harmony and Harmony 3 and EGFR progressives and frontline squamous non-small cell lung cancer. These are ones we're conducting globally with our partners at KESO in China. But at KESO actually has, as Dave alluded to, a treasure trove of data across multiple different tumor types. They've advanced into two additional phase 3s that are China specific. One is called the 306 study, which is a frontline squamous cell non-small cell lung cancer against Tizoltuzumab, the Beijing PD-1 for their market. So it's a Chinese specific squamous cell frontline study. But they're also running a frontline study of monotherapy Ivanesumab against Pembrolizumab in frontline non-small cell lung cancer. So if you look at the four studies we're conducting, three of them are against PD-1 and two of them are specifically against Pembrolizumab or Ketruda. So we are going to sort of differentiate this molecule from PD-1s dramatically by clinical data. Dave

Thank you, Alan. Really appreciate that. And so that concludes the list of questions that we've received today. So I do want to thank everyone very much for attending this morning's earnings call. As I mentioned earlier, an archived version of the webcast will be available on our website, .fmntx.com. I'd like to thank you and wish you all a great day.

Coordinator This concludes today's conference call. Thank you for your participation. You may now disconnect.